Key result
Tissue plasminogen activator (tPA) for early stroke remains underused, with 74% of UK stroke physicians uncertain of its benefits and only 30% of US neurologists finding its efficacy very convincing.
A lthough early (within 3 hours of onset) tissue plasminogen activator (tPA) has been approved as a treatment for stroke in several countries and endorsed by experts, it remains underused.Clinicians are still uncertain about whom to treat. Why Are Stroke Physicians Uncertain of the Benefits of Early tPA?An independent national survey 1 of 1716 stroke physicians in the United Kingdom reported that 74% were uncertain of the benefits of thrombolytic therapies.A recent United States survey 2 reported that less than half of the responding neurologists had administered tPA and only 30% believed the efficacy of intravenous tPA was "very convincing."alteplase (tPA) in the United Kingdom.
No takes yet. Share an insight, caveat, or question.
A 2001 study conducted an editorial in Stroke. Tissue plasminogen activator (tPA) was evaluated. Tissue plasminogen activator (tPA) for early stroke remains underused, with 74% of UK stroke physicians uncertain of its benefits and only 30% of US neurologists finding its efficacy very convincing.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: